To include your compound in the COVID-19 Resource Center, submit it here.

CPX-351: Phase II started

Celator began an open-label, U.S. Phase II trial to evaluate CPX-351 in about 36 patients with acute hematologic malignancies, including acute myelogenous leukemia

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE